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Objective: Interleukin-10, a cytokine with antiinflammatory activities, was 
studied to determine its effects on development of early lung reperfusion 
injury. Methods: Adult male rats underwent 90 minutes of left lung ischemia 
followed by 4 hours of reperfusion. Time-matched sham-operated control 
rats underwent hilar dissection but not lung ischemia. Lung injury was 
measured by vascular permeability to bovine serum albumin tagged with 
iodine 125. To evaluate the effect of exogenous interleukin-10, additional 
animals received interleukin-10 intravenously before ischemia. To assess 
the role of endogenous interleukin-10, animals received rabbit antimouse 
interleukin-10 immunoglobin G (or preimmune rabbit immunoglobin G) 
before ischemia. Results: Compared with sham control rats, ischemia- 
reperfusion control rats demonstrated significantly more lung injury. 
Animals receiving interleukin-10 had significantly less lung injury than did 
ischemia-reperfusion control rats. Animals receiving antiinterleukin-10 
had significantly more lung injury than did animals receiving preimmune 
immunoglobin G. Alveolar macrophages from animals after 90 minutes of 
lung ischemia produced more tumor necrosis factor-~ in culture than did 
unstimulated macrophages; this production was reduced significantly by 
the addition of interleukin-10 to the culture medium. Conclusion: Endoge- 
nous interleukinq0 has a protective effect against early lung reperfusion 
injury, and interleukin-10 administration can reduce lung reperfusion 
injury, perhaps in part through its ability to reduce production by alveolar 
macrophages of tumor necrosis fact0r-a, a known proinflammatory cyto- 
kine. (J Thorac Cardiovasc Surg 1996;112:1301-6) 
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L ung transplantation has emerged as a viable therapy for patients with end-stage lung disease. 
Difficulties in maintaining optimal graft function 
continue, however, to compromise patient out- 
comes. Early episodes of rejection and infection 
impair the function of lung allografts and diminish 
the long-term prognosis for patients undergoing 
lung transplantation. During the intraoperative or 
early postoperative period, lung dysfunction from 
technical difficulties or lung reperfusion injury 
threatens graft viability and patient survival. 1There 
is evidence that significant reperfusion injury pre- 
dicts a worse outcome for long-term graft survival. 2
Interleukin-10 (IL-10) has been identified as a 
potent inhibitor of early-phase inflammatory cyto- 
kine product ion) '  4 As such, it may serve to dampen 
the acute upregulation of inflammatory cytokines 
that occurs in response to many different stimuli. In 
the setting of orthotopic liver transplantation, IL-10 
release has been found to be upregulated ramati- 
cally during the early reperfusion period, 5leading to 
speculation about its eventual effects both on reper- 
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fusion injury and on the development of early graft 
rejection. 
With a rat lung model of ischemia-reperfusion, we
previously demonstrated that significant injury oc- 
curs in the reperfused lung in a bimodal pattern 
during the first 4 hours of reperfusion. 6 With this 
model, we sought to determine the effects of IL-10 
on lung reperfusion injury both through the admin- 
istration of recombinant IL-10 and through antibody 
blockade of endogenous IL-10. We also previously 
found a significant role for tumor necrosis factor-o~ 
(TNF-a)  in the development of lung reperfusion 
injury] Consequently, we attempted to determine 
whether any protective effects of IL-10 on lung 
reperfusion injury might be linked in part to down- 
regulation of TNF-o~ production in vivo. 
Materials and methods 
Reagents. All reagents were purchased from Sigma 
Chemical Company (St. Louis, Mo.) unless otherwise 
specified. Recombinant murine IL-10 was a generous gift 
from Dr. Maureen Howard (DNAX Research Institute, 
Palo Alto, CaliL). 
Animal model. Pathogen-flee adult male Long-Evans 
rats (300 to 350 g; Harlan Sprague Dawley, Inc. Indianap- 
olis, Ind.) were used for all experiments. Experimental 
protocols were approved by the University of Michigan 
Committee on the Use and Care of Animals. Animals 
were initially anesthetized intraperitoneally with 25 to 40 
mg pentobarbital. The animals were then shaved, orotra- 
cheally intubated with a 14-gauge catheter, and placed on 
a Harvard rodent ventilator (Harvard Apparatus, Inc., 
South Natick, Mass.) with supplemental oxygen (60%) at 
a rate of 75 cycles/min, with a maximum 10 cm H20 peak 
pressure and a maximum 2 cm H20 positive end-expira- 
tory pressure. All animals received 0.4 mg intramuscular 
atropine after being anesthetized. Animals received halo- 
thane through the ventilator system (0.4% to 1%) to 
maintain anesthesia as necessary during the course of the 
experiment. Each animal was then placed on its right side 
and a left anterolateral thoracotomy was carried out 
through the fifth interspace. The left pulmonary hilum was 
stripped of all neural, vascular, lymphatic, and connective 
tissue, skelet0nizing the left bronchus, pulmonary artery, 
and pulmonary vein. The inferior pulmonary ligament was 
divided as it entered the hilum. All dissection was carried 
out under an operating microscope. Each animal received 
50 U heparin in saline solution intravenously (total vol- 
ume 500/xl) through the penile vein. Five minutes after 
infusion of the heparin, the left pulmonary artery, brOn- 
chus, and pulmonary vein were sequentially occluded with 
noncrushing microvascular clamps. The lungs were kept 
moist with intermittent application of warm normal saline 
solution, and the wounds were covered with plastic film to 
prevent excessive fluid loss. Periods of ischemia were held 
constant at 90 minutes. At the end of the period of 
ischemia, the clamps were removed from the vein, bron- 
chus, and artery, in that order, and the lungs were allowed 
to ventilate and reperfuse for 4 hours. Animals received 
0.5 ml normal saline solution by subcutaneous injection 
for each hour of reperfusion to maintain hydration. Ani- 
mals were killed at the end of reperfusion by clamping of 
the right and left superior vena cavae and of the inferior 
vena cava. The left atrial appendage was then amputated, 
and the lungs were flushed with 30 ml saline solution by 
gravity infusion at 30 cm H20, through the right ventricle. 
Blood samples were obtained from the inferior vena cava 
just before the animals were killed. The left lung was then 
removed for analysis as outlined below. Animals under- 
going ischemia and reperfusion are designated as the 
positive control group (n = 6). Time-matched sham- 
oPerated control rats (sham control group, n = 4) under- 
went the identical procedure, except hat the microvascu- 
lar clamps were not applied to the hilar structures. 
Lung permeability assessment. To quantify injury to 
the lung as a result of ischemia and reperfusion, lung 
vascular permeability was measured in the following man- 
ner. Bovine serum albumin (BSA) labeled with iodine 125, 
prepared by a standard chloramine-T method, was diluted 
to approximately 3 to 5 txCi/ml in 1% BSA/phosphate- 
buffered saline solution (PBS). An 800,000 counts/min 
quantity of 125I-BSA was then brought o a final volume of 
500 txl in PBS for injection. At the time of unclamping the 
hilar structures or at the comparable time in the sham 
control group, the mix was injected into the animals 
through the penile vein. Immediately before each animal 
was killed, 1 ml blood was drawn from the inferior vena 
cava for counting. After the animal was killed and its 
pulmonary vasculature was flushed, the left lung was 
excised for counting. Each lung specimen was weighed, 
and the lungs and blood were counted separately ina gamma 
counter. All results are expressed the ratio of counts per 
minute i gm lung tissue to i ml blood: This ratio provided a
reliable measure of microvascular permeability. 
IL-10 studies. To determine the effect of exogenously 
administered IL-10, additional animals (n = 4) received 
10 txg recombinant murine IL-10 in PBS along with the 
heparin 5 minutes before induction of ischemia. These 
animals then Underwent he same ischemia-reperfusion 
protocol, with microvascular permeability determined as 
previously described. 
Protein G purified immunoglobin G (IgG) fractions of 
whole serum either from nonimmunized (preimmune) 
rabbits or from rabbits immunized against recombinant 
murine IL-10 were used to examine the effects of endog- 
enously produced IL-10 on lung ischemia-reperfusion 
injury. Animals undergoing the same ischemia-reperfu- 
sion protocol received 200/xg of either rabbit antimouse 
IL-10 IgG or preimmune IgG (n - 5 each) before the 
initiation of ischemia. Microvascular permeability was 
determined as previously described. 
Alveolar macrophage production of TNF-~. Alveolar 
macr0phages were obtained by bronchoalveolar lavage 
with Dulbecco's PBS from the lungs of either normal, 
unstimulated rats (n = 4) or selectively from the left lungs 
of animals subjected to 90 minutes of left lung ischemia 
(n = 8). After lavage, the cell suspensions were spun down 
and resuspended in RPMI medium containing 10% fetal 
bovine serum with or without 250 ng/ml recombinant 
murine IL-10. An aliquot was then obtained for cell 
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Fig. 1. Ischemic lung permeability index. Sham, Sham- 
operated control group; control, positive control group 
undergoing 90 minutes of left lung ischemia nd 4 hours 
of reperfusion; IL-IO, experimental group undergoing 
ischemia nd 4 hours of reperfusion after infusion of 10 
/xg recombinant mouse IL-10. Asterisk indicates p < 0.01 
vs control group. 
counting with a hemocytometer. A sample of 1 × 105 
macrophages in a volume of 500/xl was then pipetted into 
a culture dish and incubated for 4 hours at 37 ° C in 5% 
carbon dioxide in oxygen. At the end of the incubation 
period, the medium was removed and spun down to 
remove any cells; the supernatant was then pipetted off 
and stored at -80 ° C. The supernatant fluid was later 
analyzed for TNF-c~ content by means of a cytotoxicity 
bioassay (WEHI 164, subclone 13). 
Northern blot analysis. Total ribonucleic acid (RNA) 
was extracted from lung homogenates with a phenol/ 
guanidine isothiocyanate/chloroform-based technique 
(TRIzol Reagent; Life Technologies, Inc., Gaithersburg, 
Md.) followed by isopropanol precipitatio n. A sample 
with 12 tzg total RNA per lane was fractionated on a 1% 
agarose formaldehyde gel and blotted to a nylon mem- 
brane (Zetabind; CUNO, Inc., Meriden, Conn.) Consis- 
tency of gel loading was assessed by staining of 18S and 
28S ribosomal RNA bands on the nylon membrane with 
methylene blue. Radiolabeled probes (deoxycytidine 
triphosphate labeled with phosphorus 32) were generated 
by using polymerase chain reaction primers specific for 
the full-length open-reading frame complementary de- 
oxyribonucleic acid template of rat TNF-a. Radioactivity 
of the probes was determined by scintillation counting, 
and 1.5 × 107 counts/min radiolabeled probe was applied 
to the blot, followed by hybridization at 65 ° C overnight. 
Autoradiography of the blots was carriedout at -70 ° C on 
Kodak X-OMAT-AR film (Eastman Kodak Company, 
Rochester, N.Y.). Densitometry of autoradiographs was 
performed by means of a Fotodyne densitometer (Foto- 
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Fig. 2. Ischemic lung permeability index in animals 
undergoing ischemia nd reperfusion after receiving ei- 
ther rabbit antimouse IL-10 IgG or preimmune rabbit 
IgG. Asterisk indicates p = 0.04 vs anti-IL-10. 
dyne, Inc., Hartland, Wis.) with AMBIS software (Ambis, 
Inc., San Diego, Calif.). 
Statistical analysis. All data are presented as mean (_+ 
standard error of the mean) unless otherwise designated. 
Comparisons between groups were made with a one-way 
analysis of variance, and Tukey's procedure was used to 
determine significant differences between groups: Single 
tw0-sample comparisons were made with a two-tailed, 
unpaired Student's t test. Statistical significance was set at 
ap  level less than 0.05. 
Results 
Ischemia-reperfusion lung injury. For lung in- 
jury studies, animals underwent he standard 90 
minutes of ischemia followed by 4 hours of reperfu- 
sion (positive control group, n = 6). Time-matched 
sham control group animals underwent similar op- 
erative procedures in the absence of ischemia and 
were then left attached to the ventilator for a 
duration corresponding to the 90-minute ischemic 
time plus 4 hours (n = 4). Microvascular permeabil- 
ity was measured as described previously, by means 
of sequestration of 125I-BSA. Compared with the 
sham group, the positive control group demon- 
strated significantly more lung injury at the end of 
the 4-hour reperfusion time course (mean perme- 
ability index 0.358 _+ 0.035 vs 0.102 _+ 0.009, p < 
0.01). Animals receiving recombinant IL-10 before 
the start of ischemia (n = 4) demonstrated signifi- 
cantly less lung injury than did the positive control 
group (mean permeability index 0.167 _+ 0.028, p < 
2500 
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Fig. 3. TNF-a concentration i  supernatant of cultured 
alveolar macrophages after 4 hours at 37 ° C, measured by 
WEHI cell cytotoxicity bioassay. Unstimulated alveolar 
macrophages were lavaged from normal animals or selec- 
tively lavaged from left lungs after 90 minutes of in vivo 
ischemia. Macrophages were then cultured for 4 hours in 
medium alone or in medium containing 250 ng/ml recom- 
binant mouse IL-10. Asterisk indicates p < 0.01 vs normal 
lung macrophages; pound sign indicates p < 0.05 vs 
ischemic lung macrophages in medium without IL-10. 
0.01, Fig. 1). These data demonstrate the ability of 
exogenous IL-10 to lessen the severity of lung 
ischemia-reperfusion njury during this time course. 
Among animals treated with intravenous IgG 
before the start of ischemia, there was significantly 
more lung injury in animals receiving antibody 
against recombinant IL-10 than in animals receiving 
preimmune antibody (mean permeability index 
0.411 _+ 0.056 vs 0.237 _+ 0.044, p = 0.04, Fig. 2). 
Blocking the effects of endogenous IL-10 produced 
in response to lung ischemia-reperfusion exacer- 
bates the associated injury. 
Alveolar macrophage TNF-a production. Alve- 
olar macrophages from lungs subjected to 90 min- 
utes of ischemia produced significantly more TNF-a 
in 4 hours than did macrophages lavaged from the 
lungs of normal animals (1695 _+ 432 vs 57 _+ 37 pg 
m1-1. 4 hr 1, p < 0.01). When alveolar macro- 
phages f rom ischemic lungs were cultured in the 
presence of recombinant IL-10, they produced sig- 
nificantly less TNF-a than did macrophages from 
ischemic lungs cultured in medium alone (458 _+ 158 
vs 1695 _+ 432 pg • m1-1 • 4 hr 1,p < 0.05, Fig. 3). 
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Fig. 4. Densitometry eadings from autoradiograph of 
Northern blot of whole-lung RNA probed with radiola- 
beled complementary deoxyribonucleic a id specific for 
rat TNF-a. Higher values indicate greater relative 
amounts of TNF-a messenger RNA. Time 0 represents 
normal rat lung. All other animals underwent 90 minutes 
of isolated left lung ischemia nd the indicated reperfu- 
sion time with or without he addition of 10/xg recombi- 
nant mouse IL-10 before ischemia. 
tion by alveolar macrophages obtained from isch- 
emic lungs and point to at least one mechanism both 
for the significant lung injury that occurs as a result 
of ischemia nd reperfusion and for the reduction in 
that injury afforded by IL-10. 
TNF-a mRNA production. There was a substan- 
tial upregulation of messenger RNA for TNF-a 
early in the reperfusion time course (Fig. 4). In 
animals receiving recombinant IL-10 before the 
induction of ischemia, there was a consistent de- 
crease in the amount of TNF-a messenger RNA 
detected by Northern blot analysis, indicating that 
the effects of IL-10 on TNF-a production occurred 
at the messenger RNA level, either through inhibi- 
tion of transcription or through destabilization of 
the messenger RNA with resultant lower levels of 
message. 
Comment 
We investigated the effects of IL-10 in an in vivo 
model of single-lung ischemia-reperfusion injury. 
With this model, we previously found significant 
injury to the ischemic-reperfused lung occurring in a 
biphasic pattern during the first 4 hours of reperfu- 
sion. 6 In addition, we determined that the injury that 
occurs is mediated at least in part by the production 
of TNF-c~ during the reperfusion period. 7 Other 
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investigators have shown that IL-10 can downregu- 
late the production of several early-phase inflamma- 
tory cytokines, including TNF-a.  4' s 
We found that the administration of recombinant 
IL-10 before ischemia resulted in a marked decrease 
in the level of lung ischemia-reperfusion injury, as 
determined by microvascular permeability detected 
with radiolabeled BSA. These results correlate with 
those of others, who have shown that IL-10 is 
protective in such settings of  acute inflammatory 
upregulation endotoxemia. 9 Of particular interest in 
the setting of organ transplantation is the finding 
that IL-10 can help prevent the development of 
acute rejection. 1°' 11 
The ability to administer exogenous agents to 
prevent reperfusion injury and organ rejection is 
attractive, but the finding that a substance already 
endogenously produced has this effect is even more 
attractive. IL-10 is rapidly upregulated after reper- 
fusion of a transplanted liver 5' 12; this upregulation 
occurs in a period that suggests most of the stimulus 
occurs as a result of reperfusion itself, and not as a 
result of organ rejection. We found in our model 
that blocking endogenously produced IL-10 with 
specific antibodies resulted in a higher level of lung 
reperfusion injury, suggesting that IL-10 may al- 
ready be functioning in a homeostatic fashion to 
offset the proinf lammatory cytokines and reduce 
overall injury. 
Other investigators have shown good evidence 
that tissue macrophages may be the source of IL-10 
production during the early reperfusion period 5 and 
that endogenous IL-10 may function in an autocrine 
fashion to reduce the level of inflammatory cyto- 
kines produced by stimulated macrophages. In this 
study, we demonstrated that alveolar macrophages 
stimulated by lung ischemia produced significantly 
higher levels of  the inflammatory cytokine TNF-a,  
and that this production could be attenuated by the 
addition of IL-10 to the culture medium. This 
reduction in TNF-c~ production seems to occur at 
the messenger RNA level because IL-10 administra- 
tion before the initiation of ischemia results in 
consistent decreases in detectable TNF-o~ messenger 
RNA in lung tissue during the reperfusion time 
period. 
The finding of an endogenously produced medi- 
ator of reperfusion injury and graft rejection is a 
significant advance in our understanding of the 
immune mechanisms associated with these phenom- 
ena and with the induction of graft tolerance. More 
sophisticated adjustments of the immune response 
in the setting of organ transplantation may lead to 
improved survival with decreased complications. 
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Discussion 
Dr. Richard J. Novick (London, Ontario, Canada). I
congratulate you on excellent work, which we have been 
following for several years now. I have three questions. 
First, were the animals heparinized before hilar cross- 
clamping? Second, IL-10 decreases the production of a 
wide array of cytokines, as recently reviewed in the Journal 
of Experimental Medicine (1991;174:1209-20). Have you 
studied other cytokines, aside from TNF-c~, with respect to 
their reduced production after IL-10 administration? 
Third, have you confirmed your work in a larger animal 
model with respect o the protective ffects of IL-10 on 
ischemia-reperfusion lu g injury? 
Dr. Eppinger. In response to your first question, the 
animals were heparinized. Five minutes before the start of 
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ischemia, they received 50 U heparin, 150 U/kg, which was 
allowed to circulate before the hilar structures were 
crossclamped. Other rat models of inflammation have 
found similar effects of IL-10 on other cytokines, but such 
work has not yet been done with this model. 
Dr. Thomas M. Egan (Chapel Hill, N.C.). I have one 
question about your model. Presu.,lably this is a recover- 
able injury, and you chose 4 hours because of the maximal 
effect. What is the time course of recovery with respect to 
the microvascular injury? Have you looked at whether 
your albumin leakage diminishes with time after 4 hours? 
Dr. Eppinger. I have not done a lot of work after 4 hours. 
The only other set of animals that I have examined is at 2 
days, when there is almost complete resolution of the leak 
and the histologic aspect looked essentially normal. 
Dr. Egan. What evidence do you have that the TNF-c~ 
production that you are seeing is from alveolar macro- 
phages? 
Dr. Eppinger. The TNF-~ levels that we measured with 
the WEHI assay were on extracted alveolar macrophages. 
They were selectively plated and had harvesting of super- 
natants. I am sure that there are other cell types making 
TNF-c~ but this was the easiest way to look at it. 
Dr. Yoshifumi Naka (New York, N.Y.). I have two 
questions. First, how did you select this dose of IL-10? 
The second question is related to the first. Did you 
measure the IL-10 levels in the blood of the control 
animals? 
Dr. Eppinger. The dose of IL-10 was chosen on the 
basis of some work with mouse models to get a serum 
level of 250 ng/ml. We did not specifically measure IL-10 
levels in the blood of these animals. 
